Dormant TB beats our best drugsAugust 31, 2001New knowledge about the way tuberculosis-causing bacteria can survive in a dormant state for years in our bodies could pave the way for treatments that will finally wipe out this dread disease, experts heard today (Monday 10 September 2001) at the bi-annual meeting of the Society of General Microbiology at the University of East Anglia. US government medical researcher Dr Lawrence Wayne of the Department of Veterans Affairs Medical Center, Long Beach, California, says "We have had powerful drugs to treat tuberculosis for over 50 years, but we have failed to eradicate the disease. This is due in part to socio-economic factors as well as to AIDS, which destroys our immunity to the tubercule bacteria, but also because the bacteria can go into a dormant state in our bodies, surviving for months or years without multiplying, protected from the anti-tuberculosis drugs". According to Dr Wayne the tubercule bacteria adapt their biochemistry to conserve energy, which allows them to survive without any oxygen, although they usually need at least 10% oxygen to grow. As inflamed and infected tissues slowly run out of oxygen the bacteria stop reproducing and become dormant. The bacteria can also switch to alternative energy sources, reduce their need to make proteins, and protect their essential enzymes from breaking down. Dr Lawrence Wayne says "As medical scientists gain further genetic information about these adaptations, it should be possible to design drugs that will interfere with them and prevent the bacteria from surviving in oxygen depleted tissues, solving the problem of latent tuberculosis disease". Society for General Microbiology |
|||||||||||||||||||||
| Related Tuberculosis Current Events and Tuberculosis News Articles Multiple health concerns surface as winter, vitamin D deficiences arrive A string of recent discoveries about the multiple health benefits of vitamin D has renewed interest in this multi-purpose nutrient, increased awareness of the huge numbers of people who are deficient in it, spurred research and even led to an appreciation of it as "nature's antibiotic." Study reveals why certain drug combinations backfire Combination drug therapy has become a staple for treating many infections. For instance, doctors treat extensively drug resistant forms of tuberculosis with one drug that breaks down the pathogen's protective barriers and opens the door for another to deliver the deathblow. Drug industry, nonprofits join forces to fight world's neglected diseases Drug companies and nonprofit organizations are joining forces to develop new drugs and vaccines to target so-called "neglected" diseases that claim millions of lives in the developing world each year. U.S. and European Experts Applaud Creation of New Transatlantic Task Force on Global Antibiotic Resistance Threat Experts on both sides of the Atlantic applaud President Barack Obama and Swedish Prime Minister Fredrik Reinfeldt, representing the European Union (EU) Presidency, for establishing a transatlantic task force to address antibiotic resistance, an urgent and growing problem that threatens patient safety and public health worldwide. 1930s drug slows tumor growth Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease. There's a speed limit to the pace of evolution, Penn biologists say Researchers at the University of Pennsylvania have developed a theoretical model that informs the understanding of evolution and determines how quickly an organism will evolve using a catalogue of "evolutionary speed limits." Cell phones become handheld tools for global development Mobile phones are on the verge of becoming powerful tools to collect data on many issues, ranging from global health to the environment. Will genomics help prevent the next pandemic? This week, the Public Library of Science, an open-access publisher, presents the "Genomics of Emerging Infectious Disease," a collection of essays, perspectives, and reviews that explores how genomics-with all its associated tools and techniques-can provide insights into our understanding of emerging infectious disease. Exon-skipping drug prevents muscle wasting, maintains muscle function in dystrophin deficient mice An exon skipping PPMO has demonstrated dramatic effects in the prevention and treatment of severely affected, dystrophin and utrophin-deficient mice, preventing severe deterioration of the treated animals and extending their lifespan. Scientists take step toward simple and portable tuberculosis tests for developing world Two billion people worldwide carry the pathogen that causes tuberculosis (TB), and most of them do not even know they are infected. This is because some 90 percent of people with TB have "latent" infections. They have no symptoms, they can't spread the disease to others and the bug remains dormant in their lungs -- often for years. More Tuberculosis Current Events and Tuberculosis News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||